11:41 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Atacicept: Ph IIb ADDRESS II data

The double-blind, international Phase IIb ADDRESS II trial in 306 SLE patients receiving standard of care (SOC) showed that once-weekly 75 and 150 mg subcutaneous atacicept each missed the primary endpoint of a greater proportion...
07:00 , Sep 18, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Chris Cain, Associate Editor, and Kai-Jye Lou, Senior Writer...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

Merck KGaA, Feinstein Institute deal

Merck's Merck Serono S.A. subsidiary partnered with the institute to develop antibodies to treat systemic lupus erythematosus (SLE). Merck Serono will fund a research program at the institute on antibodies that inhibit proteins responsible for...
07:00 , Jul 2, 2012 |  BioCentury  |  Strategy

Revving the engine

After 18 months on the job, EVP of R&D Douglas Williams is making good on his promise to reignite target discovery efforts at Biogen Idec Inc. , starting with several new hires, including a CSO...
07:00 , Mar 19, 2012 |  BioCentury  |  Strategy

Remaking Merck Serono

Five years after spending $13.2 billion to acquire Serono S.A. as a growth platform, Merck KGaA finds itself with much higher pharmaceutical sales than it could have achieved on its own, but no obvious way...
08:00 , Nov 22, 2010 |  BioCentury  |  Regulation

Mild Was Enough

Leading up to last week's advisory committee meeting to discuss a BLA for lupus candidate Benlysta belimumab from Human Genome Sciences Inc. , the outcome hardly looked like a slam dunk. Based on a pair...
07:00 , Oct 4, 2010 |  BioCentury  |  Strategy

Times changed

By acquiring ZymoGenetics Inc. for $885 million in cash, Bristol-Myers Squibb Co. will get full ownership of PEG-Interferon lambda in a bet that interferons will remain an essential part of HCV treatment for years to...
07:00 , Oct 12, 2009 |  BioCentury  |  Analyst Picks & Changes

Analysts Picks & Changes

Analysts Picks & Changes...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Clinical News

Atacicept: Phase II discontinued

Zymogenetics disclosed in an SEC filing that partner Merck Serono S.A. discontinued ongoing studies for atacicept to treat MS. Merck made the decision after an Independent DMC "determined that the risk/benefit relationship did not justify...
07:00 , Oct 5, 2009 |  BioCentury  |  Finance

3Q Approvals/3Q Setbacks

3Q Approvals/3Q Setbacks...